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ABSTRACT Xeroderma pigmentosum (XP) patients have
defects in nucleotide excision repair (NER), the versatile
repair pathway that removes UV-induced damage and other
bulky DNA adducts. Patients with Cockayne syndrome (CS),
another rare sun-sensitive disorder, are specifically defective
in the preferential removal of damage from the transcribed
strand of active genes, a process known as transcription-
coupled repair. These two disorders are usually clinically and
genetically distinct, but complementation analyses have as-
signed a few CS patients to the rare XP groups B, D, or G. The
XPG gene encodes a structure-specific endonuclease that
nicks damagedDNA 3* to the lesion during NER. Here we show
that three XPGyCS patients had mutations that would pro-
duce severely truncated XPG proteins. In contrast, two sibling
XPG patients without CS are able to make full-length XPG,
but with a missense mutation that inactivates its function in
NER. These results suggest that XPGyCS mutations abolish
interactions required for a second important XPG function
and that it is the loss of this second function that leads to the
CS clinical phenotype.
Nucleotide excision repair (NER) is the process by which UV
light damage and other bulky lesions are removed from DNA.
It is a universal process that works on the same principles from
bacteria to man. The lesion is recognized, nicks are made in the
damaged strand on either side of the lesion, the oligonucleo-
tide containing the lesion is removed, and the resulting gap is
filled and sealed (reviewed in ref. 1). In human cells, the
process requires '30 polypeptides (2, 3). Defects in these
proteins can lead to some severe clinical phenotypes, notably
xeroderma pigmentosum (XP) and Cockayne syndrome (CS).
XP is an autosomal recessive disease that usually involves
deficiencies in early steps of NER, due to mutations in any one
of seven different genes (XPA–XPG), which correspond to XP
complementation groups A–G. Defects in an eighth gene, XPV
(for XP variant), account for the remaining 20% or so of XP
cases; here the defects appear to be in a postreplication repair
process rather than NER (reviewed in ref. 1). Typically, XP
patients exhibit acute sun sensitivity, dramatic skin changes,
including high incidence of cancers in sunlight-exposed areas,
and frequently also progressive neurological degeneration.
CS is another rare sun-sensitive disorder with a recessive
inheritance pattern. It is characterized by severe growth de-
fects with cachexia, neuronal demyelination, mental retarda-
tion, microcephaly, skeletal and retinal abnormalities, and
dental caries, but no cancer predisposition. Over 140 CS cases
have been reported (4) that fall into five complementation
groups. Most patients exhibit only CS symptoms and they
belong to groups CS-A and CS-B. The hallmark of cells from
these CS patients is their inability to preferentially repair DNA
damage in the transcribed strand of active genes (5–7), a
process known as strand-specific repair or transcription-
coupled repair (TCR; reviewed in refs. 8–10).
The CSA gene codes for a protein belonging to the WD-
repeat family (11), whosemembers have regulatory rather than
catalytic roles in many cellular functions, including cell divi-
sion, signal transduction, mRNA modification, and transcrip-
tion (reviewed in ref. 12). The product of the CSB gene (13)
contains a region of multiple ATPaseyputative helicase motifs
characteristic of the expanding and diverse SNF2 protein
family. Members of this family can have roles in chromatin
remodeling or maintenance, activation or repression of tran-
scription, and DNA recombination or repair (reviewed in ref.
14). How CSA and CSB function in TCR is presently unknown.
In very rare cases, complementation analyses have assigned
some CS patients to XP groups B, D, or G; some of these
XPyCS patients also present an XP phenotype. The XPB (15)
and XPD (16, 17) genes code for DNA helicases with DNA-
dependent ATPase activity that are components of TFIIH.
This multisubunit factor is required both for transcription
initiation by RNA polymerase II and also for NER (18–22), in
which it presumably is involved in opening the DNA helix in
the vicinity of the lesion.
In contrast, the product of the XPG gene (23–25) has no
documented role in transcription. It is a founding member of
the RAD2yXPG family (23–26) that comprises two related
groups of nucleases (reviewed in refs. 27 and 28). One group
includes the Schizosaccharomyces pombe rad2 protein, its
human homolog DNase IV (also called MF-1 or FEN-1), and
RAD27, the product of the YKL510 open reading frame of
Saccharomyces cerevisiae. These '43-kDa enzymes resemble
the 59 nuclease domains of bacterial DNA polymerases and are
able to cleave DNA flap structures to remove unpaired 59
regions. The second group comprises much larger proteins of
.120 kDa and includes human XPG and its yeast homologs,
the Saccharomyces cerevisiae RAD2 and Schizosaccharomyces
pombe rad13 proteins. Both XPG and RAD2 are structure-
specific endonucleases that nick damaged DNA 39 to the lesion
in an early step of NER (29–32).
To try to understand how defects in a nuclease could give
rise to two very different clinical phenotypes, we examined the
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XPG gene in the first three documented cases of combined
XP-GyCS (33–35). Here we report an unexpected common
mutational pattern in these three patients that is distinct from
that found in two sibling XP-G patients (36) with a very mild
XP phenotype and no CS symptoms. We suggest that this
pattern has implications for an important second XPG func-
tion and for the CS clinical phenotype.
MATERIALS AND METHODS
Cell Culture. Primary fibroblasts were cultured at 378C in
the presence of 5% CO2 in minimal essential medium (Se-
romed Biochrom, Berlin) supplemented with 2 mM glutamine,
heat-inactivated 15% fetal calf serum (Inotech, Dottikon,
Switzerland), 100 unitsyml penicillin, and 10 mgyml strepto-
mycin. Fibroblasts were passed twice a week irrespective of
their confluency. Lymphoblast cell lines were grown in sus-
pension at 378C in the presence of 5% CO2 in RPMI 1640
medium (Seromed) supplemented with 10% fetal calf serum.
PCR Cloning. Poly(A)1 RNA was isolated from 24 225-cm2
flasks of XPCS1LV fibroblasts with a FastTrack kit (Invitrogen).
Poly(A)1 RNA (850 ng) primed with 50 ng of random hexamers
was reverse-transcribed with Superscript II (GIBCO) and ampli-
fied with an Expand Long-template PCR kit (Boehringer Mann-
heim) using primers 59-TCTCGGCCGCTCTTAGGACG-
CAGCCGC and 59-TTTATGCATCTTTGCGACAAATTC-
ATTACAAATGG. PCR conditions were: 2 min at 948C; then 8
cycles of 15 sec at 948C, 30 sec at 688C (this temperature was
dropped 18C with each cycle), and 3 min at 688C; and then 22
cycles of 15 sec at 948C, 30 sec at 618C, and 3 min at 688C (15 sec
was added per cycle for the last 8 cycles). XPCS2LV fibroblasts
from 5 162-cm2 flasks were lysed in guanidinium isothiocyanate,
and RNA was purified by cesium chloride step-gradient centrif-
ugation. RNA (5 mg) was primed with 50 ng of p(dT)12–18
(Pharmacia) and reverse-transcribed with Superscript II. PCR
amplification was performed with the same primers as above,
using TaKaRa LA-PCR kit (Takara Shuzo, Kyoto) with the
following conditions: 4 min at 948C; then 10 cycles of 30 sec at
948C, 1 min at 688C (temperature was dropped 18C with each
cycle), 3.5 min at 728C; and then 20 cycles of 30 sec at 948C, 1 min
at 588C, and 3.5 min at 728C. The same procedure was repeated
with fibroblasts from patient 94RD27, except that amplification
was performed with High Fidelity PCR kit (Boehringer Mann-
heim). The purified PCR products were digested with EagI and
NsiI and subcloned into pBluescript II-SK1. Positive clones were
selected by hybridization and were sequenced with a deaza-GyA
T7 sequencing kit (Pharmacia). ForXPCS2LV, alleles with a C-T
polymorphismat position 335were distinguished byStyI digestion
(37) and were cycle-sequenced with an Applied Biosystems
automatic sequencer.
Oligonucleotide Typing. Reverse transcription-coupled
PCR (RT-PCR) products were amplified using Taq polymer-
ase (Perkin–Elmer) and primers 59-GATTTAATTTCCAT-
TCCAAAGGCC and 59-GTGGCTCACCATCCACGTCG.
Due to an intron located between positions 2151 and 2152,
genomic DNA and pre-mRNA were amplified with an intron-
specific 59 primer 59-TCCAGAAAGCTCTTGATGATTGC.
The denatured PCR products were slot-blotted onto a posi-
tively charged nylon membrane (Boehringer Mannheim) and
were hybridized in TMAC buffer (3 M tetramethylammonium
chloridey50 mMTriszHCl, pH 8y2 mMEDTAy53Denhardt’s
solutiony0.1% SDS) with [g-32P]ATP-labeled primers 59-
ATCACACTTTGCAC (WT) or 59-AATCACACTTGCAC
(DA) for 3 hr at 368C, and then they were washed twice for 10
min in 63 standard saline citrate and twice for 15 min in
TMAC buffer at 408C.
Restriction Analysis.A 613-bp PCR fragment was amplified
from genomic DNA fromXPCS2LV andXPCS1LV, using Taq
polymerase and primers 59-TGTCCAAAAGGAAATGAAT-
CAGC and 59-AGCAGGGCAGCTTGCATAGC. The puri-
fied fragments were then digested with FokI and analyzed on
a 5% acrylamide gel stained with ethidium bromide. Similarly,
a 100-bp PCR fragment was amplified from genomic DNA or
reverse-transcribed RNA from 94RD27 and a control patient,
using primers 59-GACCTAATCCTCATGACACC and 59-
GGTTTGAGGTAGGCC. The products were digested with
NciI and analyzed on a 6% acrylamide gel.
Western Blot Analysis. Cells were washed in PBS and proteins
were solubilized for 30min at 48C in lysis buffer (50mMTriszHCl,
pH 7.5y250 mM NaCly1 mM EDTAy0.1% Triton X-100) con-
taining protease inhibitors (2 mg/ml aprotininy2 mg/ml leupep-
tiny1 mg/ml pepstatiny0.56 mM phenylmethylsulfonyl fluoride).
Lysates were cleared by centrifugation at 13,800 3 g for 20 min
at 48C. Equivalent cell extracts (150mg of protein) were boiled for
5 min in SDS gel loading buffer, electrophoresed on 5% poly-
acrylamide gels, then transferred to Immobilon-PVDF mem-
brane (Millipore) using a semidry transfer apparatus (LKB).
Membranes were blocked for 1 hr in 3% skimmilk in TBS-T (100
mMTriszHCly0.9%NaCly0.05% Tween 20) and incubated over-
night at 48C with the appropriate antibody in 1% skim milk in
TBS-T. Mouse monoclonal antibodies to XPG (1:300; a gift of E.
Evans and R. D. Wood, ICRF Clare Hall Laboratories, South
Mimms, U.K.) and TAFII130 (1:500; Santa Cruz Biotechnology)
and rabbit polyclonal antibody to XPB p89 (1:500; Santa Cruz
Biotechnology) were used. Blots were washed three times for 15
min each in TBS-T and incubated 1 hr with a peroxidase-
conjugated anti-mouse or anti-rabbit IgG antibody (1:3000 in 1%
skim milk in TBS-T; Amersham). After three washes of 15 min
each in TBS-T, signals were detected using enhanced chemilu-
minescence (ECL); membranes were stripped and reprobed
according to the manufacturer’s recommendations (Amersham).
TCR of UV Damage. Strand-specific removal of cyclobutane
pyrimidine dimers (CPDs) was assayed by the loss of T4
endonuclease V sites (5) from the active metallothionein IA
(MTIA) gene using RNA probes (7, 38). Confluent fibroblast
cultures from patients XP125LO and XPCS1LV and a normal
individual (GM38; NIGMS Human Genetic Mutant Cell
Repository, Camden, NJ) were washed with PBS, irradiated
with 10 Jym2 254-nm UV, and then harvested immediately or
allowed to repair for 3 or 6 hr after readdition of medium. Cells
were lysed with 0.5% SDS in 10 mMTrisy10 mMEDTA, DNA
was purified and digested with EcoRI, and duplicate 10-mg
samples from each time point were incubated at 378C for 15
min with T4 endonuclease V (a gift of I. Mellon, University of
Kentucky) or with buffer alone (10 mM TriszHCl, pH 8y100
mM NaCly10 mM EDTAy10% ethylene glycol). After elec-
trophoresis through 0.7% alkaline agarose gels, DNA samples
were transferred to a GeneScreen Plus (NEN) membrane and
hybridized with strand-specific RNA probes prepared from
plasmid pZMTIIA (38). The amount of hybridization to a
10-kb fragment containing the active MTIA gene was quanti-
tated by scanning densitometry. The percent of fragments
containing no dimers (the zero class) is equal to the ratio of the
amount of full-length fragments in the enzyme-treated and
untreated samples. The average number of dimers (enzyme-
sensitive sites) per fragment was calculated from the zero class
using the Poisson expression.
RESULTS
XPCS1LV. Patient XPCS1LV, a girl with psychomotor retar-
dation and microcephaly who died at 6.5 years, was severely
sunlight-sensitive, with several pigmented cutaneous spots (33,
34). Poly(A)1RNA from a culture of her primary fibroblasts was
reverse-transcribed and the '4-kb XPG cDNA (23) was ampli-
fied by PCR. The products were cloned in a plasmid vector and
several clones were sequenced. All were found to lack a single
nucleotide within an AAA triplet at nucleotides 2170–2172,
which results in a TGA stop codon after amino acid 659 (Fig. 1A;
numbering based on EMBL and Swiss-Prot database accession
nos. X69978 and P28715, respectively). Such a deletion is char-
acteristic of a slippage error duringDNA replication. Its existence
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was independently confirmed by oligonucleotide typing, which
also revealed the presence of the wild-type XPG sequence in
genomic DNA, but not in pre-mRNA or mRNA (Fig. 1B). We
conclude that the only expressedXPG allele in patient XPCS1LV
is the one encoding a truncated protein. This would undoubtedly
compromise function, because a less severe truncation of XPG to
959 aa inactivates NER in vivo (37).
XPCS2LV. A similar procedure was applied to fibroblasts
from patient XPCS2LV, a male with extreme microcephaly,
dysmorphism, and sun-sensitive skin with several pigmented
spots, who died at age 20 months (33, 34). Surprisingly, one
XPG allele carries the same single nucleotide deletion as
XPCS1LV (Fig. 2 A and B). Although both Flemish, these two
patients are not known to be related. This shared deletion may
reflect a DNA polymerase slippage hot spot or, more likely, a
relatively recent common ancestor, because both patients also
possessed a very rare HLA DRB1-DRB3 haplotypic combi-
nation (data not shown).
The second XPG allele contains a C 3 T transition at
nucleotide 984 (Fig. 2C), which converts Arg-263 into a TGA
stop codon, resulting in an even more severely truncated
protein. This transition is located within a CpG dinucleotide
and so may have resulted from deamination of a 5-methylcy-
tosine. Its existence was independently confirmed by the loss
of a FokI restriction site from a relevant RT-PCR product
(data not shown) and from half of the PCR products from the
same region of genomic DNA (Fig. 2D). We conclude that
XPCS2LV is a compound heterozygote for these two muta-
tions that result in truncated XPG proteins.
94RD27. Patient 94RD27, a male born to healthy first cousin
Moroccan parents, had extremely severe early-onset CS and
died at 7 months (35). His fibroblasts express only one form of
XPG that lacks the T at position 2972 (Fig. 3A). This deletion
causes a frameshift after amino acid 925; another 55 aa
unrelated to XPG would be added before the next in-frame
stop codon. This deletion creates a new NciI restriction site
and, in accordance with the history of consanguinuity, the
genomic DNA is not heterozygous at this site (Fig. 3B). We
conclude that 94RD27 is homozygous for this single-base
deletion that also results in a truncated XPG protein.
XPG Protein Expression. Fig. 4 summarizes our results for
these three XP-GyCS patients and compares them with the
mutations found earlier (37) in the mildly affected XP-G
patient XP125LO (36) and in her brother, XP124LO, who
carries the same two single point mutations in XPG (data not
shown). The one on the paternal allele generates a premature
stop codon at position 960 (Fig. 4, mutation 4), whereas the
FIG. 3. Mutations in the XPG gene of patient 94RD27. (A)
Sequence of wild-type (top) and 94RD27 (bottom) RT-PCR products
showing the T deletion at position 2972. (B) NciI restriction analysis
of RT-PCR and genomic PCR products from RD9427 (lanes 94) and
a wild-type control (Ctrl). 2, Undigested products; N, NciI digests; L,
HaeIII digest of pBluescript II-SK1DNA, with fragment lengths in bp.
The T deletion creates a new NciI site (CCySGG) that is absent from
control RNA and DNA. Note that the uncut 94RD27 genomic PCR
product is slightly shorter than the control and that it is fully cut byNciI
to yield 57-bp and 42-bp fragments.
FIG. 1. Mutations in the XPG gene of patient XPCS1LV. (A)
Sequence of wild-type (top 4 rows) and XPCS1LV (bottom 4 rows)
RT-PCR products showing the single nucleotide deletion within the
AAA triplet at nucleotides 2170–2172. (B) Slot-blot hybridization of
PCR products with wild-type (WT) or mutation-specific (DA) oligo-
nucleotide probes. The wild-type sequence is present in genomic DNA
from XPCS1LV, but not in pre-mRNA or mRNA. cDNA clones WT
and DA are included as controls.
FIG. 2. Mutations in the XPG gene of patient XPCS2LV. (A and
C) Sequence of wild-type (top) and XPCS2LV (bottom) RT-PCR
products showing the sameA deletion as in XPCS1LV in one allele (A)
and the C3 T transition at position 984 in the second allele (C). (B)
Slot-blot hybridization of PCR products with wild-type (WT) or
mutation-specific (DA) oligonucleotide probes. The wild-type and
mutant sequences are present in both genomic DNA and mRNA from
XPCS2LV. Genomic DNA from XPCS1LV and XP125LO (83 DNA)
and cDNA clones WT and DA are included as controls. (D) FokI
restriction analysis of genomic PCR products from XPCS2LV (CS2)
and XPCS1LV (CS1). L, HaeIII digest of pBluescript II-SK1 DNA,
with fragment lengths in bp; F, FokI digests; 2, undigested products.
The C 3 T transition destroys a FokI site (GGATG[N]9yandy
[N]13CATCC) in one allele of XPCS2LV.
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maternal allele carries an Ala 3 Val missense mutation at
position 792 (Fig. 4, mutation 5).
As expected, no full-length XPG is detectable in fibroblast
extracts from the three XP-GyCS patients by immunoblotting
with a polyclonal antibody raised against the N terminus of
XPG (39); these Western blots also fail to detect bands
corresponding to the truncated proteins (data not shown),
suggesting that the latter may be unstable. In contrast, full-
length XPG is detectable in extracts from the sibling XP-G
patients. This is most clearly seen with lymphoblast extracts
probed with a monoclonal antibody to XPG (Fig. 5).
Removal of UV-Induced Damage. Despite the presence of
full-length XPG, XP125LO lymphoblasts have very low levels
of unscheduled DNA synthesis after UV treatment (23),
suggesting that thematernal Ala-7923Val missense mutation
severely affects global NER. This assay is too insensitive,
however, to preclude the possibility that the full-length mutant
protein may have residual NER capacity, in particular, residual
transcription-coupled NER activity. To address the latter
issue, we measured removal of CPDs from both strands of the
active MTIA gene in UV-irradiated fibroblasts from a normal
individual and from patients XP125LO and XPCS1LV. No
lesion removal was detected from either strand during 6 hr of
repair following 10 Jym2 of UV in either XP125LO or the
XP-GyCS strain (Fig. 6). In contrast, the normal fibroblasts
removed dimers rapidly and strand-selectively, with 69% re-
moved from the transcribed strand in 6 hr, compared with 30%
from the nontranscribed strand. We conclude that these XP-G
and XP-GyCS cells are completely defective in both global
NER and transcription-coupled NER of UV damage.
DISCUSSION
Our results confirm the complementation analyses that impli-
cate XPG in certain forms of CS (34, 35), and they extend these
analyses by identifying three causative mutations in this gene.
The three patients analyzed here presented unusually severe
early-onset CS, and they died in infancy or early childhood. All
three XP-GyCS patients had few clinical manifestations of XP,
perhaps because of limited sun exposure and their early death.
Their striking common pattern was an inability to produce
full-length XPG. Recently, a fourth XP-GyCS patient was
reported (XP20BE), a boy with severe CS symptoms and
XP-type pigmentation, but no skin cancers, who also died in
early childhood (41). A clear prediction from our results is that
he, and any future XP-GyCS patients, would have mutations
that prevent the production of full-length XPG protein.
The paternal allele of the mildly affected XP-G siblings
would also be expected to generate a truncated version of
XPG, similar to that produced in XP-GyCS patient 94RD27
(Fig. 4). However, the XP-G siblings canmake full-length XPG
(Fig. 5), thanks to the maternal allele that carries an Ala-792
3 Val missense mutation. Several lines of evidence indicate
that this single amino acid change abolishes NER activity.
XP125LO lymphoblast cells exhibit only background levels of
unscheduled DNA synthesis (23). UV resistance is not re-
stored to these cells by expression of a full-length XPG cDNA
containing the missense mutation (37). The location of this
mutation in a highly conserved region suggests that it perturbs
the endonuclease active site (23, 37). The crystal structure of
bacteriophage T4 RNase H, another member of the RAD2y
XPG protein family, also indicates that the affected amino acid
lies within the active site, adjacent to a glutamate needed for
magnesium binding and catalytic activity (42). Finally, and
most directly, lymphoblast extracts from patient XP125LO are
incapable of making the normal NER 39 incision on a cisplatin-
containing substrate (43), and fibroblasts from the same
patient are unable to remove UV-induced pyrimidine dimers
from either strand of an active gene (Fig. 6).
We conclude that the clinical presentation of CS in patients
with XPGmutations is unrelated to the incision function of XPG
inNER.Rather, we propose that theXP-GyCSphenotype results
from disruption of protein–protein or protein–DNA interactions
that are important for a second XPG function. XPG and its
homologs are distinguishable from the shorter proteins in the
RAD2yXPG family by the large distance between two regions of
sequence similarity (23–27). If these N and I regions (Fig. 4) are
juxtaposed in XPG, as they are in T4 RNase H (42), clearly there
is scope for the residues between them to adopt a conformation
suitable for a second function. What might this function be, and
how is it related to CS?
As outlined earlier, XPG is one of five defective gene
products implicated in this clinical phenotype. Two others, the
XPB and XPD ATPasesyhelicases, are subunits of the basal
transcription factor TFIIH (18–22). This finding led to the
FIG. 5. Western blot analysis of lymphoblast extracts probed with
antibodies to XPG, TAFII130, and XPB. The lymphoblast lines XPG82
(lane 82) and XPG83 (lane 83) are derived from patients XP124LO
and XP125LO, respectively; XPG81 (lane 81) is from their obligate
heterozygote mother. DS2 is a wild-type lymphoblast line (40). Note
that the XPG protein, which has a predicted molecular mass of 133
kDa, is present in the two XP-G patients, but in reduced amounts, and
that it migrates very close to the 205-kDa myosin marker.
FIG. 4. Alignment of wild-type XPG with those predicted in the
three XP-GyCS patients and the two sibling non-CS XP-G patients.
The number of amino acids in each protein is listed on the right.
Hatched areas indicate: N and I, conserved regions; NLS, putative
bipartite nuclear localization signal; C, basic domain. Mutations: 1,
Single A deletion within nucleotides 2170–2172; 2, nonsense C 3 T
transition at nucleotide 984; 3, single T deletion at position 2972 (black
area indicates the frameshift between amino acids 926 and 980); 4,
nonsense G3 T transversion at nucleotide 3075; and 5, missense C3
T transition at nucleotide 2572.
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suggestion that certain mutations in XPB and XPD may affect
only NER and thereby give rise to XP, whereas other kinds of
mutations in these genes, and indeed in genes for other TFIIH
subunits, may have additional subtle effects on transcription
that result in the more complex and pleiotropic features of CS
and other ‘‘transcription syndromes’’ (44, 45). Consistent with
this hypothesis, the XPD mutations in the two known XP-
DyCS patients are distinct from those found in patients with
XP-D alone (46, 47). The XPB frameshift mutation found in
the first XP-ByCS patient results in a severe NER defect but
also a modest decrease in transcriptional activity in vitro (48).
Although experimental evidence is lacking, the sequence
motifs found within CSA and CSB (11, 13) may also hint at
their possible involvement in transcription.
It is more difficult to apply a transcription hypothesis to the
XP-G form of CS, because XPG is not an integral component of
TFIIH and it has no known function in transcription. However,
XPG copurifies with TFIIH under some chromatographic con-
ditions (49), and XPG has been reported to interact with several
TFIIH subunits (50). Most recently, evidence has been presented
for a tight association between RAD2 and yeast TFIIH (51). It is
conceivable that certain mutations within XPG andRAD2 could
perturb interactions with TFIIH and cause subtle defects in
transcription. However, the nature of the XP-GyCS mutations
reported here, and the failure to detect the resulting truncated
XPG proteins, suggest that XPG would be nonfunctional and
incapable of interacting with TFIIH in these rare patients. The
mutations identified in CS-A (11) and CS-B (9) patients would
also be expected to result in total loss of function. Similarly,
disruption mutants of RAD2 and of the yeast homologs of CSA
andCSB (RAD28 andRAD26, respectively) do not affect viability
(52–54). Thus, in contrast to XPB and XPD, the other three
proteins implicated in CS and their yeast counterparts are not
essential for RNA polymerase II transcription.
In seeking a molecular explanation of CS, we suggest that
attention be focused on the DNA repair defect that is specific to
CS-A andCS-B patients, namely, their inability to carry out TCR.
A causal relationship between CS and the NER version of TCR
is difficult to imagine because most XP groups are not associated
with CS. In particular, many Japanese XP-A patients with essen-
tially no NER activity present a very severe XP phenotype but no
CS symptoms (55). However, in normal human cells, TCR
corrects not only UV-induced DNA damage but also lesions
induced by ionizing radiation; the latter process requires CSB but
not XPA (7). Since damage from ionizing radiation under
biological conditions is largely caused by hydroxyl radicals and
other reactive oxygen species, its spectrum is very similar to that
of spontaneous oxidative damage generated during normal cel-
lular metabolism (56, 57). Transcriptionally active, rapidly pro-
liferating cells would be most exposed to such natural metabolic
damage, and hence would be particularly at risk if TCR were
impaired or nonfunctional. Thus, rather than being due to a
transcriptional defect, the CS clinical phenotype may be related
to a deficiency in TCR of endogenous DNA damage (7, 8),
perhaps during critical time windows in early development.
Recently we have provided evidence that XPG is required
for TCR of such damage (58), and we suggest that this
represents the second XPG function. Cells from the three
XP-GyCS patients characterized here are unable to preferen-
tially remove thymine glycols from transcribed strands of
active genes whereas this TCR activity occurs at normal levels
in cells from XPG patient XP125LO and fromXP-A and XP-F
patients (58). These results strongly suggest that TCR of
oxidative damage is independent of the XPG incision function
in NER, and even of NER altogether. Instead, this activity
presumably is initiated by glycosylases and AP endonuclease in
a base excision repair pathway (reviewed in ref. 1). We suspect
that this pathway requires at least a transient interaction
between XPG and TFIIH, and perhaps other proteins, to
displace RNA polymerase II stalled at a lesion (51, 59). Rather
than having a catalytic role, XPG may have an assembly
function in this pathway, similar to its suggested role in helping
to establish the NER preincision complex (3).
Mutations in three of the five genes implicated in CS have been
shown to result in a partial (CSA) or complete (CSB and XPG)
deficiency inTCRof oxidative base damage (7, 58). It would seem
reasonable to expect similar defects in cells from XP-ByCS and
XP-DyCS patients. XP-GyCS cells exhibit an additional defect, a
decreased rate of removal of oxidative damage from the genome
as a whole (58). This may contribute to the unusually severe
phenotype presented by the XP-GyCS patients, and it may also
hint at an additional XPG function in a base excision repair
pathway that is not coupled to transcription. In conclusion, a
positive and perhaps causal relationship exists between an inabil-
ity to produce full-length XPG, an inability to remove oxidative
base damage from active genes, and the appearance of the
devastating CS clinical phenotype.
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FIG. 6. Strand-selective repair of CPDs in the MTIA gene. (A)
Human primary fibroblasts were exposed to 10 Jym2 UV and were
allowed to repair for the indicated times. EcoRI-digested genomic
DNA was treated (1) or not (2) with T4 endonuclease V, electro-
phoresed, blotted, and hybridized with RNA probes that distinguish
the transcribed (TS) and nontranscribed (NTS) strands of the MTIA
gene. (B) Repair values calculated from scanning densitometry mea-
surements of the hybridization signals in the autoradiogram. The mean
of all six 0 time values, 0.71 6 0.03 (SD) CPD per 10 kb, was set equal
to 100%. Filled symbols represent TS; open symbols represent NTS.
Circles, normal fibroblasts, GM38; squares, XP-G fibroblasts
XP125LO; and triangles, XP-GyCS fibroblasts, XPCS1LV.
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